• The 2025 DREAMS Grant Program awards $50,000 each to two non-profit organizations working to advance equity, accessibility and inclusion for those living with Duchenne in the U.S., EU or U.K.
• Announced in advance of World Duchenne Awareness Day on September 7, grants are designed to fund projects supporting the Duchene community on a global scale

BOSTON, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the recipients of its third annual DREAMS Grant Program. Jett Foundation (U.S.) and Parent Project aps (Italy) will each be awarded $50,000 to support programs that are working to better identify, understand and reach members of the Duchenne muscular dystrophy community who are currently underrepresented or underserved.

“Since the beginning, our commitment to the Duchenne community has gone beyond therapeutic development. In fact, one of the most meaningful parts of our work at Entrada is engaging with and learning from patients and families around the world. Expanding this year’s DREAMS Grant Program applicant pool to include organizations based in the U.S., EU and U.K. showcases this commitment in action,” said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics. “Jett Foundation and Parent Project aps are driving long-term, transformative change for those living with Duchenne in the U.S. and Italy, and we look forward to their ongoing efforts to address critical needs of the Duchenne community while promoting inclusivity, equity and accessibility for all.”

Entrada DREAMS Grant Recipients

• Jett Foundation is a US-based non-profit organization headquartered in Massachusetts, committed to extending and enriching the lives of individuals affected by Duchenne. The foundation empowers families and builds community through its family support services, educational initiatives and adaptive recreational opportunities. Funds from the 2025 DREAMS Grant will support the organization’s Camp Promise, the foundation’s year-round, no-cost program designed to support individuals living with Duchenne and other neuromuscular disorders – specifically those aged 18 and older who are often excluded from traditional recreational programming. With the grant support, Jett Foundation aims to empower more than 250 campers in 2025 through programming focused on independent living, self-advocacy and employment preparation.
• Parent Project aps is an Italian non-profit organization dedicated to supporting individuals with Duchenne and Becker muscular dystrophy and their families. Founded by parents, the organization focuses on promoting scientific research, improving access to care and advocating for policies that enhance quality of life. The DREAMS Grant will enable Parent Project aps to deliver home-based care and teleconsultation services to families living in underserved regions of Southern Italy who face systemic barriers such as limited access to specialized clinics, transportation challenges and fragmented health and social services. The initiative will ensure continuity of clinical, psychological and social support for families while addressing inequities in care access and creating a replicable model tailored to marginalized communities.

Entrada thanks its independent grant review committee of respected neuromuscular leaders and advocates who selected the Entrada DREAMS Grant recipients in the third year of the annual program, including:

• Sean Baumstark, Founder, de:terminence and Co-Host, Two Disabled Dudes Podcast
• Keisha Greaves, Founder, Girls Chronically Rock and Chief Executive Officer, GCR Adaptive Solutions
• Amaris Sánchez-Larragoity, PsyD, Psychologist
• Aravindhan Veerapandiyan, MD (Dr. Panda), Assistant Professor of Pediatrics, Division of Pediatric Neurology, Arkansas Children’s Hospital

“Being part of the Entrada DREAMS Grant Review Committee for the past three years has been truly meaningful for me,” said Keisha Greaves, Founder of Girls Chronically Rock and Chief Executive Officer of GCR Adaptive Solutions. “As a woman living with muscular dystrophy and an advocate for disability representation, I know how important it is to uplift organizations that are creating real change in our community. It was powerful to read through so many inspiring applications, and I’m proud to have played a role in supporting this important work. I can’t wait to see how these grantees continue to impact lives in the Duchenne space and beyond.”

About Entrada Therapeutics

Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV™)-therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through this proprietary, versatile and modular approach, Entrada is advancing a robust development portfolio of RNA- and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. The Company’s lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

For more information about Entrada, please visit our website, www.entradatx.com, and follow us on LinkedIn.

Investor Contact
Karla MacDonald
Chief Corporate Affairs Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.

Patient Advocacy Contact
Sarah Friedhoff
Head of Patient Advocacy
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact
Megan Prock McGrath
CTD Comms, LLC
This email address is being protected from spambots. You need JavaScript enabled to view it.